# Kiora Pharmaceuticals Inc: overview KPRX · Nasdaq · CIK 1372514 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/kprx.md) · [Financials](/companies/kprx/financials.md) · [Filings](/companies/kprx/filings.md) · [Insiders](/companies/kprx/insiders.md) Latest reported revenue: [$0](/filings/0001372514-26-000024.md) for Q4 FY2025, three months to 2025-12-31, from the 10-K filed Mar 25, 2026 (XBRL us-gaap:Revenues, accession 0001372514-26-000024). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.0](/filings/0001372514-25-000078.md) | [0.0 d](/filings/0001372514-26-000024.md) | [0.0](/filings/0001372514-25-000044.md) | [0.0](/filings/0001372514-25-000061.md) | [0.0](/filings/0001372514-25-000078.md) | [0.0 d](/filings/0001372514-26-000024.md) | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.81)](/filings/0001372514-25-000078.md) | not reported | [(0.52)](/filings/0001372514-26-000047.md) | [(0.54)](/filings/0001372514-26-000074.md) | [0.01](/filings/0001372514-25-000078.md) | not reported | [(0.58)](/filings/0001372514-26-000047.md) | [(0.34)](/filings/0001372514-26-000074.md) | | Free cash flow | $k | [920 d](/filings/0001372514-25-000078.md) | [(2,297) d](/filings/0001372514-26-000024.md) | [(2,704)](/filings/0001372514-26-000047.md) | [(3,836) d](/filings/0001372514-26-000074.md) | [(1,274) d](/filings/0001372514-25-000078.md) | [(2,259) d](/filings/0001372514-26-000024.md) | [(3,166)](/filings/0001372514-26-000047.md) | [(1,915) d](/filings/0001372514-26-000074.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001410578-22-001931.md) | not reported | [0.0](/filings/0001372514-25-000012.md) | [16.0](/filings/0001372514-26-000024.md) | [0.0](/filings/0001372514-26-000024.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | [28.2%](/filings/0001372514-26-000024.md) | not reported | | Net margin | % | not reported | not reported | not reported | [22.4%](/filings/0001372514-26-000024.md) | not reported | | Diluted EPS | $ per share | [(57.12)](/filings/0001372514-23-000050.md) | [(18.55)](/filings/0001372514-24-000026.md) | [(24.25)](/filings/0001372514-25-000012.md) | [0.87](/filings/0001372514-26-000024.md) | [(2.64)](/filings/0001372514-26-000024.md) | | Free cash flow | $m | [(10.7)](/filings/0001372514-23-000050.md) | [(10.4)](/filings/0001372514-24-000026.md) | [(9.6)](/filings/0001372514-25-000012.md) | [8.6](/filings/0001372514-26-000024.md) | [(10.1)](/filings/0001372514-26-000024.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/kprx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $1.2m | 438,471 | | New +438,471 | | [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $441.7k | 167,941 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $305.1k | 116,011 | | Added +66,478 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $233.5k | 88,792 | | New +88,792 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $195.2k | 74,202 | | New +74,202 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $78.4k | 29,824 | | New +29,824 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $70.3k | 26,717 | | Reduced −21,133 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $52.2k | 19,861 | | Unchanged | | [Scientech Research LLC](/funds/2011556.md) | 2026-06-30 | $49.3k | 18,746 | | New +18,746 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $34.3k | 13,030 | | Unchanged | ## Recent filings [All 921 filings](/companies/kprx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-29 | 07:03 ET | [8-K](/filings/0001372514-26-000088.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001372514-26-000088 | | 2026-09-08 | 07:05 ET | [8-K](/filings/0001372514-26-000079.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001372514-26-000079 | | 2026-08-19 | 07:01 ET | [8-K](/filings/0001372514-26-000077.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001372514-26-000077 | | 2026-08-07 | 07:03 ET | [8-K](/filings/0001372514-26-000075.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001372514-26-000075 | | 2026-08-07 | 07:02 ET | [10-Q](/filings/0001372514-26-000074.md) | Quarterly report, period 2026-06-30 | 0001372514-26-000074 | | 2026-06-18 | 07:02 ET | [8-K](/filings/0001372514-26-000063.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001372514-26-000063 | | 2026-06-11 | 18:39 ET | [8-K](/filings/0001372514-26-000059.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001372514-26-000059 | | 2026-05-08 | 07:07 ET | [8-K](/filings/0001372514-26-000048.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001372514-26-000048 | | 2026-05-08 | 07:06 ET | [10-Q](/filings/0001372514-26-000047.md) | Quarterly report, period 2026-03-31 | 0001372514-26-000047 | | 2026-04-30 | 17:11 ET | [DEF 14A](/filings/0001372514-26-000040.md) | Proxy statement, period 2026-04-16 | 0001372514-26-000040 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001372514-26-000024.md), filed Mar 25, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1372514 - Tickers: KPRX, KPHMW - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 07:04 ET. No prices; not investment advice.